Phase I Study to Assess the Safety and Tolerability of AZD5438 in Patients With Advanced Solid Malignancies
Phase 1
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Neoplasms
Both
Neoplasms
Trial Information
Phase I Study to Assess the Safety and Tolerability of AZD5438 in Patients With Advanced Solid Malignancies
Inclusion Criteria:
- Advanced solid malignancy
- Cancer refractory to standard treatments or for which no standard therapy exits
Exclusion Criteria:
- Radiotherapy within 3 weeks of the start of treatment
- Investigational product within the last 3 weeks
- Systemic cytotoxic anti-cancer therapy within the last 3 weeks
- Any significant clinical disorder that makes it undesirable for the patient to
participate
Type of Study:
Interventional
Study Design:
Primary Purpose: Treatment
Authority:
United States: Food and Drug Administration
Study ID:
D0110C00005
NCT ID:
NCT00088790
Start Date:
July 2004
Completion Date:
December 2005
Related Keywords:
- Neoplasms
- advanced, solid, malignancies
- Neoplasms
Name | Location |
|---|---|
| Research Site | Beverly, Massachusetts |
| Research Site | Albany, New York |
